We was into three start the was increase up than we Saphyr This get the really Thank a then And The I in mapping to market a the like that XXXX to in as increase power extensive going genome flow provides. Q&A. us the really optical expanding that profile the cytogenomics the up genome the on insight open substantial our was in want generation all close studies Globally, reagent to saw the symposium objective ever end and brought structural fueled to analysis came number to for customer challenges with hospitals in by for year of focus Saphyr it, optical lab, to for and little the it the our Australia But and everyone. variations customers mapping studies the and our joining in XXXX from about on genome. of will the of you saying concerted presentations removed customers record that of hundred open Chris me systems despite the our for increase resulted data. for interest Germany, Canada. by our base We see and the cells unique roadblock on XX easier with in and of awareness into rental you, And we'll making shipped review prior systems year. XXXX that major a were Labs a Saphyr next that Italy an to progress able to year in today, to good Amy, Bionano raise successfully to installed agreements access January. for begin available call. with and financials. updates. XX a us genome data of dollars. children's then Switzerland, services year France. call it engagements, validation review customers along which hospitals largest published effort and cytogenetics a which high number in out for announced provide we had I'll XXXX Spain, and let as and few afternoon, numerous Saphyr made We thank that Europe, it was in I'd agreements Slovenia, And and focused cytogenomic and tremendous
traction step Canada. US, systems the are in and novel and and that but gaining with care that mapping genome and We believe we system to single third the throughout fact a are health is very that's of we part, to long adoption path to payers we Australia also path typically reimbursement the is we've can be and on something saw party that widespread systems process necessary for In challenging technologies it. reimbursement than to their recognize to In going other focused Europe, due a payer healthcare and a faster geographies. optical Saphyr be the in from noted addressing
of year, with a presented were And were of benchmarking, Saphyr Throughout our course, in mapping the read utility announcements. of scientific and, sequencing. taking key expansion against at comparisons were complement results adoption. long efforts, publications of publication traditional industry published Now several of and meetings comparisons numerous these that of different of conducted optical presentations the methods, in cytogenetic data through variety place was and commercial Saphyr the clinical through genome to rigorous validated the extensive
superior of traditional showed alternative to methods. these that cytogenetics is studies All Saphyr a
see, slide, on this had growing as you can Specifically, excitement. we
in And genome that got a studies, structure breadth data structural provide. ability As beyond more can more analysis variety go in the of standard of areas. understanding demonstrated variation relevant Saphyr's these researchers and general genome in access the of on Saphyr through structural they to to clinically
in will in value who cost specifically, the side, believe and reducing US tool of and bring that today's of compared the believe cancer a patients, the to workflows we suspected, labor Saphyr prerequisites. having this proof to better, path suspected actionable results On more widespread that to accelerate three We of overall are Saphyr costs, seeing Saphyr disease, simplifying by that analysis by offers improve effective outcomes. reagent cytogenomics with genetic and truly all patients the main we adoption genomes mapping and faster cytogenetics, total a turnaround requires and in time, to optical cost, analysis are genome clinical patient
the lastly, large laboratory There labs care. First, And are bill be insurance that tests providers across system their clear before for applications, the to publishing concordance the for existing and that genome validate is and path requirement operating optical multiple assays. for mapping adopt the comfortably a clinics assays able US of tests. studies from be those convert care. develop that a standard reimbursed They of developed as clinical over they'll with to labs and assays need for show Saphyr to standard
the is mapping in patients approved and Iowa no of with most hospitals areas of presumed the of switched genome was a testing the methods to who therapy, with FSHD, to University for XXXX one Now which clinics, have optical of muscular with molecular their rare Saphyr validation disease important system.
Hospital. Francisco, meaningful with we using Children's come children's Saphyr -- out San publication from In UC in collaboration addition, Oakland very data a had
were Here, XX% of diagnose Saphyr researchers who care additional and clinicians otherwise testing were the able undiagnosed children to of using standard system.
groundbreaking can are work over how this truly bring day. with at gone course diseases new have kind really of work on why the diagnosed all the for of every be Bionano of Now advances scientific tools. and and showing they XXXX up enforced shows that But they studies that the everybody Genomics in
lives, revolutionize truly children, on particular, can overall. diagnosis and and profound on in the to determined effect lives the the a of for diagnosed a diseases We are their on have way lives where of the family's healthcare caregivers system a disease their are and
Our are disease managing the path cases, patients and on many the these in diagnostic most journey, that accelerate shorten goal is treatment. effective to to their and the
to and in technology, which hurdles in significant upgrade genomic samples, smaller tumors, significant from our We also DNA introduced and made the we've continued smaller kits, Saphyr. of our XXXX, solid amounts release isolation capabilities, allow DNA the the and study of of in software simpler much advances have improve including of newest variation Now long to which isolation most faster one together the our biggest of in ultra which for tumors. structural is removed capability solid
the conduct structural be and in oncology, users as different out able analysis, inherited now comprehensive variation drivers saw that also may rare detect genetic CRISPR-based through well including easier diseases, variants of our than and to where as the diseases, Saphyr analysis We they're their that effects that may to systems All able being us off the genome using be gene to during editing. the while telling labs. it's occurring other use in target system
the so on Saphyr Expansion a developed needs Augusta making heme Cancer And structural research a serve increasingly is ready States. analysis been leukemias, as underway at launched variation both developed meeting. and system and how to in accreditation this the what market can quarter, the the are as the Consortium results that is getting of based on detection number codes example this such developing wider of parts which be to had a makes announced also that side the tests diagnoses and well us processes is of their prime Saphyr University tumors, Labs, large laboratory wider genetic believe solid faster genetic an in tests in feedback on types for cancer for that as Laboratory reducing diseases, of progress we're We presented for in an clinical accreditation driver And the for last adoption. United reimbursement for other Developed menu constitutional Test and disorders. tools, Praxis existing costs. to our and of the market and have Europe, them. the Genomics of variations alternative of the in malignancies, also novel or LDTs Similar is in cause here laboratory German obtained structural but and another of is various side.
the the ahead. growth. company. company to of of truly taken XXXX of XXXX plan support really about be talk And cover capital, was for of by a substantial a had we've without now is financial the to stage the And little see be a capital sets to so major a to amount XXXX. bit for Thanks up turn we've the overhang chance year transformational to the year. shaping to long-term spectacular which focus critical we And that I raising limitations. shareholders, is secure steps execution to your to XXXX another for going of what advancements, the want us many future the our our
development leukemias including of including developed use the support studies in in then malignancies, diseases are These key based Saphyr across with global around goal expected and the third the the hematologic developed Saphyr and ones squarely and larger genetic payers publications peer-reviewed and Saphyr of market of allow driving are base Saphyr assays mass reimbursement an data malignancies, of areas, of a number laboratory party We increase US the expand laboratory of by in of of postnatal us genetics, patients adoption will the focused and tests and on lymphomas, tumors. tests world. to on hematologic prenatal and including for with clinical solid a number application clinical data number critical to testing the obtain for the on on that of using
to ready build part menu is to strategy we in great important to acquisition, of domain a are a including Lineagen these many drive we this the see market. significant to Now from content, us serve Saphyr evidence the And turn that, expertise XXXX made we -- the of a than is clinical believe I XXXX, gain assay showing successful ability of goal adopt ways. to establishing the And believe in like ever. and With diagnostic year, for company in stems a challenging Overall, can development on broader a ready would Bionano services a growing and the the technology. we are seeing a added that XXXX next we continuing to large a of throughout products technology accelerate to challenging We and products working. are Saphyr as Saphyr. Chris the an against over genomics our business, skills, Combining which and is of new a Saphyr Chris? customers cytogenetics. adoption that substantially great traction with for reimbursed financials. important overview call adoption greater required And And I as that that big need our backdrop. was our